Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy Hannah L Kalvin Fiona D Ehrich Ronak H Shah Matthew J Adamow Vladislav Raber Colleen A Maher Jenna Kleman Deborah A G McIntyre Alexander N Shoushtari Allison Betof Warner Margaret K Callahan Parisa Momtaz Omar Eton Suresh G Nair Jedd D Wolchok Paul B Chapman Michael F Berger Katherine S Panageas Michael A Postow

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Adaptively dosed nivo-ipi responses are durable and resemble historical data for conventional nivo-ipi. Baseline IL6 and circulating tumor DNA changes during treatment warrant further study as biomarkers of nivo-ipi response.

Keyphrases

circulating tumor
cell free
circulating tumor cells
single molecule
electronic health record
machine learning
big data